ONC earnings

Total global revenues of $1.5 billion for the first quarter, an increase of 35% from the prior year Foundational BRUKINSA (zanubrutinib) global revenues of $1.1 billion for the first quarter, an increase of 38% from the prior year Diluted GAAP Earnings per American Depository Share (ADS) of $1.96 for the first quarter; non-GAAP diluted Earnings per ADS of $3.24 for the first quarter BeOne Medicines Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company, today announced financial results and corporate updates from the first quarter of 2026. John V. Oyler, Co-Founder, Chairman, and CEO, BeOne, said: "These strong first-quarter results reinforce BeOne's conti

Total global revenues of $1.5 billion and $5.3 billion for the fourth quarter and full year, increases of 33% and 40% from the prior-year periods Global BRUKINSA (zanubrutinib) revenues of $1.1 billion and $3.9 billion for the fourth quarter and full year, increases of 38% and 49% from the prior-year periods Diluted GAAP Earnings per American Depository Share (ADS) of $0.58 and $2.53 for the fourth quarter and full year; non-GAAP diluted Earnings per ADS of $1.95 and $8.09 for the fourth quarter and full year Full year 2026 total revenue guidance of $6.2 billion to $6.4 billion BeOne Medicines Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company, today announ

Third quarter total revenues increased 41% to $1.4 billion versus third quarter 2024 Global BRUKINSA® (zanubrutinib) revenues increased 51% to $1.0 billion versus third quarter 2024 Diluted GAAP Earnings per American Depository Share (ADS) of $1.09, non-GAAP diluted Earnings per ADS of $2.65 47 abstracts accepted at American Society of Hematology (ASH) Annual Meeting BeOne Medicines Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company, today announced financial results and corporate updates from the third quarter of 2025. "These strong financial results reinforce our position as a global oncology leader with exceptional topline growth and a strong balance sheet,

Second quarter total revenues increased 42% to $1.3 billion versus second quarter 2024 Global BRUKINSA revenues increased 49% to $950 million versus second quarter 2024 Reported diluted GAAP Earnings per American Depositary Share (ADS) of $0.84, non-GAAP diluted Earnings per ADS of $2.25 Anticipate 20+ milestones in next 18 months across hematology and solid tumor pipeline BeOne Medicines Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company, today announced financial results and corporate updates from the second quarter of 2025. "Our strong second quarter performance reinforces our trajectory as a global oncology powerhouse and underscores our proven abilit

First quarter 2025 total revenues increased 49% to $1.1 billion with BRUKINSA® (zanubrutinib) global sales increasing 62% to $792 million on strong demand growth versus first quarter 2024 Achieved GAAP profitability and significantly improved operating cash flow Advanced late-stage hematology and solid tumor pipelines with plan to host Investor R&D Day on June 26 Secured shareholder approval to rename the Company to BeOne Medicines Ltd. and redomicile to Switzerland BeiGene, Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company that will change its name to BeOne Medicines, Ltd., today announced financial results and corporate updates from the first quarter 2025.

BeiGene, Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company that intends to change its name to BeOne Medicines Ltd., will report its first quarter 2025 financial results on Wednesday, May 7, 2025 before the financial markets open. Following the release of the financials, the Company will host a live webcast with management at 8:00 a.m. ET. The conference call will be webcast live and a link to the webcast can be accessed from the investors section of the Company's website at http://ir.beigene.com/, https://hkexir.beigene.com/, https://sseir.beigene.com/. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the schedul

Total global revenues of $1.1 billion and $3.8 billion for the fourth quarter and full year, increases of 78% and 55%, respectively; narrowed GAAP operating loss and achieved full-year positive non-GAAP operating income Global BRUKINSA revenues of $828 million and $2.6 billion for the fourth quarter and full year, increases of 100% and 105%, respectively; progressed pivotal-stage programs for BCL2 inhibitor sonrotoclax and BTK CDAC BGB-16673 Advanced six and 13 New Molecular Entities (NMEs) into the clinic in the fourth quarter and full year, respectively; anticipate multiple data readouts for innovative solid tumor programs in 1H 2025 Full year 2025 revenue guidance of $4.9 billi

BeiGene, Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company that intends to change its name to BeOne Medicines Ltd., will report its fourth quarter and full year 2024 financial results on Thursday, February 27, 2025 before the financial markets open. Following the release of the financials, the Company will host a live webcast with BeiGene management at 8:00 a.m. ET. The conference call will be webcast live and a link to the webcast can be accessed from the investors section of BeiGene's website at http://ir.beigene.com/, https://hkexir.beigene.com/, https://sseir.beigene.com/. To ensure a timely connection, it is recommended that participants register at least 15 min